91 related articles for article (PubMed ID: 29023121)
1. Discovery of 3,5-Diphenyl-4-methyl-1,3-oxazolidin-2-ones as Novel, Potent, and Orally Available Δ-5 Desaturase (D5D) Inhibitors.
Fujimoto J; Okamoto R; Noguchi N; Hara R; Masada S; Kawamoto T; Nagase H; Tamura YO; Imanishi M; Takagahara S; Kubo K; Tohyama K; Iida K; Andou T; Miyahisa I; Matsui J; Hayashi R; Maekawa T; Matsunaga N
J Med Chem; 2017 Nov; 60(21):8963-8981. PubMed ID: 29023121
[TBL] [Abstract][Full Text] [Related]
2. A Novel Orally Available Delta-5 Desaturase Inhibitor Prevents Atherosclerotic Lesions Accompanied by Changes in Fatty Acid Composition and Eicosanoid Production in
Takagahara S; Shinohara H; Itokawa S; Satomi Y; Ando A; Yamamoto T; Suzuki H; Fujimoto T; Kubo K; Ikeda S
J Pharmacol Exp Ther; 2019 Nov; 371(2):290-298. PubMed ID: 31488602
[TBL] [Abstract][Full Text] [Related]
3. A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice.
Yashiro H; Takagahara S; Tamura YO; Miyahisa I; Matsui J; Suzuki H; Ikeda S; Watanabe M
PLoS One; 2016; 11(11):e0166198. PubMed ID: 27832159
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2.
Xu Y; Yang X; Zhao P; Yang Z; Yan C; Guo B; Qian SY
Free Radic Biol Med; 2016 Jul; 96():67-77. PubMed ID: 27101738
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of serum dihomo-γ-linolenic acid level and estimated Δ-5 desaturase activity in patients with hepatic steatosis.
Matsuda M; Kawamoto T; Tamura R
Obes Res Clin Pract; 2017; 11(1):34-43. PubMed ID: 26964726
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
[TBL] [Abstract][Full Text] [Related]
7. Associations of estimated Δ-5-desaturase and Δ-6-desaturase activities with stroke risk factors and risk of stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study.
Daneshmand R; Kurl S; Tuomainen TP; Virtanen JK
Br J Nutr; 2017 Feb; 117(4):582-590. PubMed ID: 28382895
[TBL] [Abstract][Full Text] [Related]
8. Effects of compound-326, a selective delta-5 desaturase inhibitor, in ApoE knockout mice with two different protocols for atherosclerosis development.
Nagase H; Takagahara S; Satomi Y; Ando A; Kubo K; Ikeda S
J Pharm Pharm Sci; 2021; 24():71-83. PubMed ID: 33600308
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
[TBL] [Abstract][Full Text] [Related]
10. [Synthesis and antibacterial activities of 7-{4-[2-[2-substituted-4-((5S)-5-acetylaminomethyl-2-oxo-oxazolidin-3-yl)}-phenyl] -ethyl]-piperazin-1-yl}-fluoroquinolones].
Yu HJ; Zhou WC
Yao Xue Xue Bao; 2006 Oct; 41(10):990-9. PubMed ID: 17184119
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro antibacterial activities of novel oxazolidinones.
Srivastava BK; Jain MR; Solanki M; Soni R; Valani D; Gupta S; Mishra B; Takale V; Kapadnis P; Patel H; Pandya P; Patel JZ; Patel PR
Eur J Med Chem; 2008 Apr; 43(4):683-93. PubMed ID: 17611001
[TBL] [Abstract][Full Text] [Related]
12. 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.
Duplantier AJ; Efremov I; Candler J; Doran AC; Ganong AH; Haas JA; Hanks AN; Kraus KG; Lazzaro JT; Lu J; Maklad N; McCarthy SA; O'Sullivan TJ; Rogers BN; Siuciak JA; Spracklin DK; Zhang L
Bioorg Med Chem Lett; 2009 May; 19(9):2524-9. PubMed ID: 19328692
[TBL] [Abstract][Full Text] [Related]
13. 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts.
Brnardic EJ; Fraley ME; Garbaccio RM; Layton ME; Sanders JM; Culberson C; Jacobson MA; Magliaro BC; Hutson PH; O'Brien JA; Huszar SL; Uslaner JM; Fillgrove KL; Tang C; Kuo Y; Sur SM; Hartman GD
Bioorg Med Chem Lett; 2010 May; 20(10):3129-33. PubMed ID: 20409708
[TBL] [Abstract][Full Text] [Related]
14. 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor.
Ueda S; Terauchi H; Yano A; Ido M; Matsumoto M; Kawasaki M
Bioorg Med Chem Lett; 2004 Jan; 14(2):313-6. PubMed ID: 14698148
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies.
Yang T; Chen G; Sang Z; Liu Y; Yang X; Chang Y; Long H; Ang W; Tang J; Wang Z; Li G; Yang S; Zhang J; Wei Y; Luo Y
J Med Chem; 2015 Aug; 58(16):6389-409. PubMed ID: 26212502
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid delta(5)-desaturase mRNA is regulated by dietary vitamin A and exogenous retinoic acid in liver of adult rats.
Zolfaghari R; Cifelli CJ; Banta MD; Ross AC
Arch Biochem Biophys; 2001 Jul; 391(1):8-15. PubMed ID: 11414679
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and in vivo activity of novel inhibitors of delta-5 desaturase for the treatment of metabolic syndrome.
Baugh SD; Pabba PK; Barbosa J; Coulter E; Desai U; Gay JP; Gopinathan S; Han Q; Hari R; Kimball SD; Nguyen HV; Ni CY; Powell DR; Smith A; Terranova KM; Wilson A; Yu XC; Lombardo VK
Bioorg Med Chem Lett; 2015 Sep; 25(18):3836-9. PubMed ID: 26235947
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
Xue T; Ding S; Guo B; Zhou Y; Sun P; Wang H; Chu W; Gong G; Wang Y; Chen X; Yang Y
J Med Chem; 2014 Sep; 57(18):7770-91. PubMed ID: 25179681
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation of the FADS1 FADS2 gene cluster and n-6 PUFA composition in erythrocyte membranes in the European Prospective Investigation into Cancer and Nutrition-Potsdam study.
Zietemann V; Kröger J; Enzenbach C; Jansen E; Fritsche A; Weikert C; Boeing H; Schulze MB
Br J Nutr; 2010 Dec; 104(12):1748-59. PubMed ID: 20691134
[TBL] [Abstract][Full Text] [Related]
20. Novel 4-N-substituted aryl but-3-ene-1,2-dione derivatives of piperazinyloxazolidinones as antibacterial agents.
Varshney V; Mishra NN; Shukla PK; Sahu DP
Bioorg Med Chem Lett; 2009 Dec; 19(23):6810-2. PubMed ID: 19837588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
